The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line.
Francesco Grossi
Honoraria - Roche
Claudio Sini
No relevant relationships to disclose
Giulia Barletta
No relevant relationships to disclose
Erika Rijavec
No relevant relationships to disclose
Carlo Genova
No relevant relationships to disclose
Maria Giovanna Dal Bello
No relevant relationships to disclose
Paolo Pronzato
No relevant relationships to disclose
Paola Venturino
Employment or Leadership Position - Roche
Giovanni L. Pappagallo
No relevant relationships to disclose